Skip to main content

Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer

This is a preview of subscription content, access via your institution.

References

  1. Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Holm Damgaard L, Buchholtz K, Skalshøi Kjær M, Balendran C, Myers RP, Loomba R, Noureddin M (2022) Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. J Hepatol. https://doi.org/10.1016/j.jhep.2022.04.003

  2. Polyzos SA, Kountouras J, Zavos C, Deretzi G (2012) Nonalcoholic fatty liver disease: Multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 46:272–284

    Article  PubMed  Google Scholar 

  3. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP (2012) Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome. Expert Opin Pharmacother 13:287–288

  4. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384:1113–1124

    CAS  Article  PubMed  Google Scholar 

  5. Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VW, Greenbloom S, Jayakumar S, Shiffman ML, Freilich B, Lawitz EJ, Gane EJ, Harting E, Xu J, Billin AN, Chung C, Djedjos CS, Subramanian GM, Myers RP, Middleton MS, Rinella M, Noureddin M (2020) Cilofexor, a Nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a Phase 2 Randomized Controlled Trial. Hepatology 72:58–71

    CAS  Article  PubMed  Google Scholar 

  6. Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, Bhandari BR, Gunn N, Caldwell SH, Goodman Z, Wapinski I, Resnick M, Beck AH, Ding D, Jia C, Chuang JC, Huss RS, Chung C, Subramanian GM, Myers RP, Patel K, Borg BB, Ghalib R, Kabler H, Poulos J, Younes Z, Elkhashab M, Hassanein T, Iyer R, Ruane P, Shiffman ML, Strasser S, Wong VW, Alkhouri N (2021) Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology 73:625–643

    CAS  Article  PubMed  Google Scholar 

  7. Polyzos SA, Kang ES, Boutari C, Rhee EJ, Mantzoros CS (2020) Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 111S:154203

    Article  PubMed  Google Scholar 

  8. Polyzos SA, Kechagias S, Tsochatzis E (2021) Review article: non-alcoholic fatty liver disease and cardiovascular diseases - associations and treatment considerations. Aliment Pharmacol Ther 54:1013–1055

    Article  PubMed  Google Scholar 

  9. Lawitz EJ, Bhandari BR, Ruane PJ, Kohli A, Harting E, Ding D, Chuang JC, Huss RS, Chung C, Myers RP, Loomba R (2022) Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with Cilofexor/Firsocostat. Clin Gastroenterol Hepatol. https://doi.org/10.1016/j.cgh.2021.12.044

Download references

Author information

Authors and Affiliations

Authors

Contributions

SAP: Conception and design, review of the literature, acquisition of articles, interpretation of articles, drafting the article and revising it critically for important intellectual content, and final approval of the version to be submitted.

NK: Conception and design, review of the literature, acquisition of articles, interpretation of articles, drafting the article and revising it critically for important intellectual content, and final approval of the version to be submitted.

Both authors ensure that the article is original work, has not been previously published, and is not under consideration for publication elsewhere.

Corresponding author

Correspondence to Stergios A. Polyzos.

Ethics declarations

Conflict of interest

SAP has no conflict of interest.

NK has given talks, attended conferences and participated in trials sponsored by Amgen, Astra Zeneca, Bausch Health, Boehringer Ingelheim, Elpen, Novartis, Novo Nordisk, Sanofi, Servier, Viatris, Vianex, and WinMedica.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Polyzos, S.A., Katsiki, N. Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer. Hormones (2022). https://doi.org/10.1007/s42000-022-00379-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s42000-022-00379-6

Keywords

  • Cilofexor
  • Combination
  • Fibrosis
  • Firsocostat
  • Nonalcoholic fatty liver disease
  • Nonalcoholic steatohepatitis
  • Obesity
  • Semaglutide
  • Steatosis
  • Treatment